Implications for treating patients with progressive, unresectable locally advanced or metastatic HER2-positive breast cancer with tucatinib in combination with capecitabine and trastuzumab.
EP. 1: Standard of Care for R/R Metastatic HER2+ Breast Cancer
September 8th 2021Current treatment options and outcomes for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy, with special insight regarding the management of brain metastasis and visceral disease.
EP. 2: HER2+ Breast Cancer: Key Takeaways From HER2CLIMB
September 8th 2021An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer.